| 1 |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71(3)：209-249.
|
| 2 |
Killock D. Frontline nivolumab combinations improve os in escc[J]. Nat Rev Clin Oncol，2022，19(4)：219.
|
| 3 |
Thrift AP. Global burden and epidemiology of barrett oesophagus and oesophageal cancer[J]. Nat Rev Gastroenterol Hepatol，2021，18(6)：432-443.
|
| 4 |
Hagen PV, Dekken HV, Rozema T, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med，2012, 22: 2074-2084.
|
| 5 |
Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (neocrtec 5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol，2018，36(27)：2796-2803.
|
| 6 |
Kojima T, Shah MA, Muro K, et al. Randomized phase Ⅲ keynote-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol，2020，38(35)：4138-4148.
|
| 7 |
Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (keynote-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet，2021，398(10302)：759-771.
|
| 8 |
Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (attraction-3): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol，2019，20(11)：1506-1517.
|
| 9 |
Lin DC, Wang MR, Koeffler HP. Genomic and epigenomic aberrations in esophageal squamous cell carcinoma and implications for patients[J]. Gastroenterology，2018，154(2)：374-389.
|
| 10 |
Smyth EC, Gambardella V, Cervantes A, et al. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy[J]. Ann Oncol，2021，32(5)：590-599.
|
| 11 |
Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the neocrtec5010 randomized clinical trial[J]. JAMA Surg，2021，156(8)：721-729.
|
| 12 |
Eyck BM, Lanschot JJB, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled cross trial[J]. J Clin Oncol，2021，39(18)：1995-2004.
|
| 13 |
Shapiro J, Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol，2015，16(9)：1090-1098.
|
| 14 |
Huang TC, Hsu CH, Lin CC, et al. Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer[J]. Jpn J Clin Oncol，2015，45(11)：1023-1028.
|
| 15 |
Klevebro F, Alexandersson von Döbeln G, Wang N, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction[J]. Ann Oncol，2016，27(4)：660-667.
|
| 16 |
Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1) [J]. Eur J Cancer，2021，144：232-241.
|
| 17 |
Gao L, Lu J, Zhang P, et al. Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2) [J]. J Gastrointest Oncol，2022，13(2)：478-487.
|
| 18 |
He W, Leng X, Mao T, et al. Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma[J]. Oncologist，2022，27(1)：18-28.
|
| 19 |
Liu J, Yang Y, Liu Z, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma[J]. J Immunother Cancer，2022，10(3)：e004291.
|
| 20 |
Lv H, Tian Y, Li J, et al. Neoadjuvant sintilimab plus chemotherapy in resectable locally advanced esophageal squamous cell carcinoma[J]. Front Oncol，2022，12：864533.
|
| 21 |
Yan X, Duan H, Ni Y, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE) [J]. Int J Surg，2022，103：106680.
|
| 22 |
He W, Mao T, Yan J, et al. Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy[J]. Ann Transl Med，2021，9(8)：706.
|
| 23 |
Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol，2018，19(7)：965-974.
|
| 24 |
Fang HY, Chao YK, Chang HK, et al. Survival outcomes of consolidation chemoradiotherapy in esophageal cancer patients who achieve clinical complete response but refuse surgery after neoadjuvant chemoradiotherapy[J]. Dis Esophagus，2017，30(2)：1-8.
|
| 25 |
Biere SS, Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial[J]. Lancet，2012，379(9829)：1887-1892.
|
| 26 |
Li B, Zhang Y, Miao L, et al. Esophagectomy with three-field versus two-field lymphadenectomy for middle and lower thoracic esophageal cancer: long-term outcomes of a randomized clinical trial[J]. J Thorac Oncol，2021，16(2)：310-317.
|